474 related articles for article (PubMed ID: 31837960)
1. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
[TBL] [Abstract][Full Text] [Related]
2. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.
Shlyankevich J; Mehta NN; Krueger JG; Strober B; Gudjonsson JE; Qureshi AA; Tebbey PW; Kimball AB
Am J Med; 2014 Dec; 127(12):1148-53. PubMed ID: 25149424
[TBL] [Abstract][Full Text] [Related]
3. Double trouble: psoriasis and cardiometabolic disorders.
Mahyoodeen NG; Crowther NJ; Tikly M
Cardiovasc J Afr; 2018 May/Jun 23; 29(3):189-194. PubMed ID: 29293257
[TBL] [Abstract][Full Text] [Related]
4. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives.
Kapniari E; Papadimitriou P; Dalamaga M; Makavos G; Piaserico S; Egeberg A; Ikonomidis I; Papadavid E
Curr Vasc Pharmacol; 2020; 18(6):592-609. PubMed ID: 32445456
[TBL] [Abstract][Full Text] [Related]
5. Cardiometabolic risk in psoriasis: differential effects of biologic agents.
Kaplan MJ
Vasc Health Risk Manag; 2008; 4(6):1229-35. PubMed ID: 19337536
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
Menter MA; Mehta NN; Lebwohl MG; Gottlieb AB; Mendelsohn AM; Rozzo SJ; Leonardi C
J Drugs Dermatol; 2020 Aug; 19(8):703-708. PubMed ID: 32845115
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk.
Visser MJE; Tarr G; Pretorius E
Front Immunol; 2021; 12():688861. PubMed ID: 34335591
[TBL] [Abstract][Full Text] [Related]
8. Potential Immunological Links Between Psoriasis and Cardiovascular Disease.
Sajja AP; Joshi AA; Teague HL; Dey AK; Mehta NN
Front Immunol; 2018; 9():1234. PubMed ID: 29910818
[TBL] [Abstract][Full Text] [Related]
9. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases.
Liberale L; Ministrini S; Carbone F; Camici GG; Montecucco F
Basic Res Cardiol; 2021 Mar; 116(1):23. PubMed ID: 33770265
[TBL] [Abstract][Full Text] [Related]
10. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
Puig L
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.
Furue M; Tsuji G; Chiba T; Kadono T
Intern Med; 2017; 56(13):1613-1619. PubMed ID: 28674347
[TBL] [Abstract][Full Text] [Related]
13. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.
Raggi P; Genest J; Giles JT; Rayner KJ; Dwivedi G; Beanlands RS; Gupta M
Atherosclerosis; 2018 Sep; 276():98-108. PubMed ID: 30055326
[TBL] [Abstract][Full Text] [Related]
14. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.
Hu MY; Yang Q; Zheng J
Clin Exp Dermatol; 2020 Oct; 45(7):836-840. PubMed ID: 32789979
[TBL] [Abstract][Full Text] [Related]
15. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis.
Baumer Y; Ng Q; Sanda GE; Dey AK; Teague HL; Sorokin AV; Dagur PK; Silverman JI; Harrington CL; Rodante JA; Rose SM; Varghese NJ; Belur AD; Goyal A; Gelfand JM; Springer DA; Bleck CK; Thomas CL; Yu ZX; Winge MC; Kruth HS; Marinkovich MP; Joshi AA; Playford MP; Mehta NN
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321372
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis and its comorbidities.
Onumah N; Kircik LH
J Drugs Dermatol; 2012 May; 11(5 Suppl):s5-10. PubMed ID: 22644770
[TBL] [Abstract][Full Text] [Related]
17. Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation.
Miller AM; McInnes IB
Curr Pharm Des; 2011; 17(1):1-8. PubMed ID: 21222645
[TBL] [Abstract][Full Text] [Related]
18. High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index.
García-Escobar A; Lázaro-García R; Cabrera JÁ; Jurado-Román A; Moreno R
Int J Cardiovasc Imaging; 2024 Apr; 40(4):945-948. PubMed ID: 38558330
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis.
Lockshin B; Balagula Y; Merola JF
J Am Acad Dermatol; 2018 Aug; 79(2):345-352. PubMed ID: 29477740
[TBL] [Abstract][Full Text] [Related]
20. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
Ait-Oufella H; Libby P; Tedgui A
Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
